Philips receives FDA 510(k) clearance for its Rembra platform, expanding access to faster, more precise CT imaging across frontline care and cancer treatment planning

April 22, 2026 Clearances for Rembra CT, Rembra RT, and Areta RT enable high-throughput imaging at scale and elevate precision across the cancer care pathway Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Rembra platform of scanning systems, including Rembra CT, Rembra RT and Areta RT. The newly cleared systems are designed to help healthcare providers respond to growing demand for imaging and radiation therapy planning by helping to improve speed, efficiency, and access to high-quality imaging.